Abstract:Background: Biomarker identification is one of the major and important goal of functional genomics and translational medicine studies. Large scale -omics data are increasingly being accumulated and can provide vital means for the identification of biomarkers for the early diagnosis of complex disease and/or for advanced patient/diseases stratification. These tasks are clearly interlinked, and it is essential that an unbiased and stable methodology is applied in order to address them. Although, recently, many, primarily machine learning based, biomarker identification approaches have been developed, the exploration of potential associations between biomarker identification and the design of future experiments remains a challenge. Methods: In this study, using both simulated and published experimentally derived datasets, we assessed the performance of several state-of-the-art Random Forest (RF) based decision approaches, namely the Boruta method, the permutation based feature selection without correction method, the permutation based feature selection with correction method, and the backward elimination based feature selection method. Moreover, we conducted a power analysis to estimate the number of samples required for potential future studies. Results: We present a number of different RF based stable feature selection methods and compare their performances using simulated, as well as published, experimentally derived, datasets. Across all of the scenarios considered, we found the Boruta method to be the most stable methodology, whilst the Permutation (Raw) approach offered the largest number of relevant features, when allowed to stabilise over a number of iterations. Finally, we developed and made available a web interface ( https://joelarkman.shinyapps.io/PowerTools/ ) to streamline power calculations thereby aiding the design of potential future studies within a translational medicine context. Conclusions: We developed a RF-based biomarker discovery framework and provide a web interface for our framework, termed PowerTools, that caters the design of appropriate and cost-effective subsequent future omics study.

A flexible framework for minimal biomarker signature discovery from clinical omics studies without library size normalisation

biosigner: A New Method for the Discovery of Significant Molecular Signatures from Omics Data

Discovery of sparse, reliable omic biomarkers with Stabl

Small molecule biomarker discovery: Proposed workflow for LC-MS-based clinical research projects

Robust biomarker screening from gene expression data by stable machine learning-recursive feature elimination methods

Coupling bootstrap with synergy self-organizing map-based orthogonal partial least squares discriminant analysis: Stable metabolic biomarker selection for inherited metabolic diseases

Addressing statistical challenges in the analysis of proteomics data with extremely small sample size: a simulation study

A dropout-regularized classifier development approach optimized for precision medicine test discovery from omics data

Leveraging DNA methylation to create Epigenetic Biomarker Proxies that inform clinical care: A new framework for Precision Medicine

A Novel Strategy for Rapidly and Accurately Screening Biomarkers Based on Ultraperformance Liquid Chromatography-Mass Spectrometry Metabolomics Data.

A random forest based biomarker discovery and power analysis framework for diagnostics research

A Flexible Approach for Predictive Biomarker Discovery

MetaFS: Performance assessment of biomarker discovery in metaproteomics

Identification of a Novel Biomarker Panel for Breast Cancer Screening

Feature Selection Methods for Protein Biomarker Discovery from Proteomics or Multiomics Data.

Enabling scalable clinical interpretation of ML-based phenotypes using real world data

Assessment of a high-throughput mass spectrometry method to accelerate biomarker discovery in clinical cancer cohorts using volumetric absorptive microsampling (VAMS) devices.

Performance, Transparency and Time. Feature selection to speed up the diagnosis of Parkinson's disease

Scale-invariant biomarker discovery in urine and plasma metabolite fingerprints

Electro-Optical Multiclassification Platform for Minimizing Occasional Inaccuracy in Point-of-Care Biomarker Detection

A three-stage approach to identify biomarker signatures for cancer genetic data with survival endpoints